CYTR
CytRx Corporation [CYTR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CYTR Stock Summary
In the News
CYTR Financial details
Company Rating
-
Market Cap
0
Income
-3.62B
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
10 Nov 2022
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
0.01
P/C
-
P/FCF
-
Quick Ratio
0.26
Current Ratio
0.44
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-130.95
EPS next Y
-
EPS next Q
-
EPS this Y
32602.86%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
208.44%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-125.58%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-593%
ROE
3122%
ROC
6.26%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-9%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.05-0.86
52W High
-
52W Low
-
RSI
46.75
Rel Volume
-
Avg Volume
-
Volume
7.65K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-5.26%
-
-
-
-
Beta
2.10148
-
-
Volatility
0.02%, 0.02%
Prev Close
10.97%
Price
0.18
Change
11.11%
Company Profile
- Employee 3
- CEO Mr. Steven Kriegsman
- Headquarters Los Angeles,CALIFORNIA,US
- IPO Date 1986-11-10
-
Website
https://www.cytrx.com 
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
